PMID: 6110861Mar 21, 1981Paper

Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase

Lancet
H M TylerM J Parry

Abstract

Pairs of healthy male volunteers received single oral doses (5-200 mg) of UK-37,248-01, a selective thromboxane synthetase inhibitor. Measurement of total thromboxane B2 (TXB2) concentrations in serum from venous blood showed that production of TXB2 was inhibited in a dose-related manner, with peak inhibition 1 h after doses of 50 mg and above. After 100 mg and 200 mg doses TXB2 production was inhibited by more than 90% at 1 h and about 50% at 6 h. Plasma drug assays confirmed oral absorption. About one-third of the dose was excreted unchanged in the urine, most within the first 4 h. Small and transient increases in bleeding time (within the normal range, except in one subject) were seen after the 50, 100, and 200 mg doses and corresponded to low levels of TXB2 production; whole blood clotting time was unchanged. There were no clinically relevant changes in heart rate or blood-pressure, other than a transient reduction in standing systolic blood-pressure and heart rate in one subject who received 200 mg. There were no side-effects and routine laboratory tests revealed no important abnormalities.

References

Feb 1, 1979·The Journal of Clinical Investigation·P NeedlemanA Raz

❮ Previous
Next ❯

Citations

Mar 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·W DorschW Müller
Jan 1, 1984·Agents and Actions·G de Gaetano, V Bertelé
Nov 1, 1989·British Journal of Plastic Surgery·K R KnightB M O'Brien
Oct 15, 1984·European Journal of Pharmacology·M J SheaB R Lucchesi
Feb 12, 1985·European Journal of Pharmacology·C Kumar, M Singh
Mar 1, 1983·The American Journal of Cardiology·P WalinskyL Wiener
Feb 1, 1983·Prostaglandins, Leukotrienes, and Medicine·R J OuwendijkJ E Vincent
Nov 14, 2002·British Journal of Pharmacology·J P De La CruzF Sánchez de La Cuesta
Sep 1, 1983·The Journal of Clinical Investigation·R WinnJ Hildebrandt
Oct 1, 1983·The Journal of Clinical Investigation·G A FitzGeraldA K Pedersen
Nov 1, 1984·The Journal of Clinical Investigation·F R DeRubertisR Saito
Apr 1, 1985·The Journal of Clinical Investigation·T M CoffmanP E Klotman
Nov 1, 1985·Journal of Neurosurgery·J B Leslie, W D Watkins
Aug 7, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Plínio Cunha SathlerHelena Carla Castro
Dec 1, 1986·Journal of Cardiac Surgery·W J GreeleyW D Watkins
Aug 1, 1985·British Journal of Haematology·F E Preston, M Greaves
Aug 1, 1986·The Journal of Surgical Research·S PriceR Winn
Mar 19, 1983·Lancet
Jun 1, 1990·Scandinavian Journal of Clinical and Laboratory Investigation·R Jelnes
Mar 1, 1983·Stroke; a Journal of Cerebral Circulation·S Moncada
Jul 1, 1990·Circulation Research·D C HockingA Johnson
May 1, 1982·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S Moncada
Dec 1, 1985·Circulation·G A FitzGeraldA K Pedersen
May 1, 1986·Stroke; a Journal of Cerebral Circulation·S KaplanM Walker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.